Q-omics provides the consensus-scored SAMD14 profile across patient tissues and cancer cell-line models. SAMD14 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SAMD14 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SAMD14 RNA expression shows 16,135 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where SAMD14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAMD14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAMD14 survival associations across molecular data types. SAMD14 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAMD14 RNA expression–survival associations across cancer types. High SAMD14 expression shows unfavorable associations in BLCA, MESO, LUSC, UVM and BRCA, but favorable associations in LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SAMD14 RNA expression.
This table summarizes SAMD14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SAMD14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAMD14 shows lower tumor expression in LUAD and higher tumor expression in KIRC, HNSC, COAD, KIRP and THCA. The KIRC box plot shows higher SAMD14 RNA expression in tumor versus normal tissue (log2 FC = +1.282, t-test p < 0.001).
This table shows molecular features associated with SAMD14 in patient tissues and cancer cell lines. In patient samples, SAMD14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SAMD14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
